# Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients

> **NCT00707954** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 61 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** TA-7284
- **DRUG:** Placebo of TA-7284

## Key facts

- **NCT ID:** NCT00707954
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00707954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00707954, "Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00707954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*